CECOG Academy

www.cecog.org

 

CECOG Academy
T

2021 ASCO Paradigm Changing Updates on Pancreatic Ductal Adenocarcinoma: Considering Clinical Trial Data

By CECOG Academy FEATURING Talia Golan
By CECOG Academy FEATURING Talia Golan
39 views
July 6, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Featured Video

13:36
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss
Pancreatic Cancer
31:05

Modern Treatment Approaches in mPDAC: Overview of 1L/2L Options and …

CECOG Academy

G. Prager

184 views
23:51

2021 ASCO Paradigm Changing Updates on Pancreatic Ductal Adenocarcin…

CECOG Academy

T. Golan

39 views
35:20

2021 ASCO Abstracts Review in PAD: Palliative Care, Neoadjuvant Trea…

CECOG Academy

T. Golan, G. Prager, C. Yoo, E. Van Cutsem

49 views
28:06

Molecular Testing for Treatment Stratification on PDAC Patients: Whe…

CECOG Academy

C. Neuzillet, P. Hammel, M. Ikeda

573 views
30:57

PDAC Expert Panel Discussion: Differences in Clinical Practice, Turn…

CECOG Academy

C. Neuzillet, P. Hammel, M. Ikeda

27 views
23:53

mPAC Oligometastatic Disease Expert Discussion: Eligibility for 2nd …

CECOG Academy

T. Seufferlein, M. Falconi, K. Uesaka

17 views
30:28

Updates on mPAC: Is There a Target Group for Oligometastatic Disease…

CECOG Academy

T. Seufferlein

81 views
31:35

Expert Discussion on Resectable/Borderline-Resectable PAC: Gemcitabi…

CECOG Academy

G. Prager, T. Macarulla, E. Van Cutsem, C. Cheng Ean

101 views
23:59

Neoadjuvant Treatment Concepts for Resectable/Borderline-Resectable …

CECOG Academy

T. Macarulla

151 views
29:00

Expert Discussion on PRODIGE 24 Data on FOLFIRINOX vs. Gemcitabine a…

CECOG Academy

G. Prager, J. Taieb, H. Wasan, J. Oh Park

373 views
26:51

Adjuvant Treatment Options for PAC Patients: Who Should Receive FOLF…

CECOG Academy

J. Taieb

109 views